April 17th 2024
A group of researchers recently aimed to investigate the prognosis of patients with NSCLC that lacked a spouse, family members, or friends to support them during cancer treatment.
Revolutionizing Early-Stage NSCLC Treatment: Pathologists’ Key Insights into Predicting Pathologic Responses to Immunotherapies
View More
Community Practice Connections™: 20th Annual Winter Lung Conference
View More
Medical Crossfire®: Key Strategies to Prioritize Testing and the Evolving Role of Genomic Alterations in Providing Precision NSCLC Care
View More
Breaking Down Biomarkers in Non–Small Cell Lung Cancer: A Case-Based Discussion for the Oncology Nurse
View More
Go To PER in Chicago
May 31, 2024 - June 2, 2024
Register Now!
The Top 10 Oncogenic Drivers in NSCLC for 2023: What You Need to Know on Tumor Testing, Targets, and Treatment Strategies to Move the Field Forward
View More
Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation–Positive NSCLC: A Lung Cancer Tumor Board
View More
Expanding the Armamentarium of Actionable Mutations in NSCLC: Uncovering the Potential of CEACAM5 as a Therapeutic Target
View More
25th Annual International Lung Cancer Congress®
July 25-27, 2024
Register Now!
24th Annual International Lung Cancer Congress®
View More
Engaging the Multidisciplinary Care Team to Optimize Care of Patients With EGFR Mutation-Positive NSCLC: A Lung Cancer Tumor Board
View More
Pathology Implications for CEACAM5 as a Therapeutic Target in Advanced NSCLC
View More
Medical Crossfire®: What Are Effective Strategies for Onco-Nurses to Improve Outcomes in Patients with Small Cell Lung Cancer?
View More
Advances In™: Aligning Pathology and Oncology Efforts in the Community to Improve NSCLC Care
View More
Community Practice Connections: 7th Annual School of Nursing Oncology™
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Virtual Show Me the Data™: How HER2, HER3, and TROP2 Targeted Strategies Will Impact Evolving Paradigms in NSCLC
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process
View More
How CEACAM5 Expression Can Be Measured and Leveraged in NSCLC Care: Current Developments & Future Therapeutic Opportunities
View More
Lung Cancer Tumor Board®: Enhancing Multidisciplinary Communication to Optimize Immunotherapy in Stage I-III NSCLC
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Matching Treatment to Patient with EGFR-Mutant Lung Cancer: Mutation Subtypes, Co-Mutations, and Managing Resistance
View More
Improving Outcomes Across Frontline and R/R SCLC Care in Community Treatment Settings
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
18th Annual New York Lung Cancers Symposium®
View More
22nd Annual Winter Lung Cancer Conference®
January 31, 2025 - February 2, 2025
Register Now!
Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…
View More
21st Annual Winter Lung Cancer Conference® In Line Session: Advent of TROP2-Directed ADCs In Lung Cancer
View More
Study Suggests Role of Immunogenetic Associations in Lung Cancer Risk
March 7th 2024In the U.S., nearly 200,000 new cases of lung cancer were reported in 2020, with over 100,000 deaths. While the number of lung cancer deaths has generally decreased over the past 20 years, lung cancer remains the leading cause of cancer deaths in the US and is the third most common type of cancer.
Read More
Study: Long-Term Smoking Cessation Linked to Lower Cancer Risk, Even with Relapses
February 6th 2024It is well-known that smoking is linked to a higher risk of cancer, and those who smoke can lower their risk by quitting. However, it remains unclear exactly how many years of continued smoking cessation are needed to see a substantial risk reduction.
Read More
Trodelvy Falls Short As NSCLC Treatment, Taking Some of the Shine Off Antibody-Drug Conjugates
January 23rd 2024Gilead's share price fell 10% today after it announced that Trodelvy, an antibody-drug conjugate, failed to meet its overall survival end point in a trial testing it as treatment for metatstatic non-small cell lung cancer.
Read More
Liquid Biopsy May Guide Treatment and Improve Outcomes in Lung Cancer, New Study Shows
January 8th 2024While tissue biopsy is currently recommended as the gold standard for determining mutations in non-small cell lung cancer, its success is not guaranteed, prompting the consideration of the liquid biopsy method as a viable alternative.
Read More
Immunotherapy vs. Chemotherapy as Second-line Treatment for NSCLC
March 1st 2023A real-world evidence study shows an advantage in median overall survival among non-small cell lung cancer patients who were treated with second-line immunotherapy compared to those treated with chemotherapy. Multivariable analysis showed healthcare resource utilization was comparable.
Read More
The Mainstreaming of Targeted Lung Cancer Treatment
September 14th 2021Treatments aimed at certain mutations have proliferated and moved upstream to earlier-stage lung cancers. But there are many questions about insurance coverage and which tests to use to identify the biomarkers that help guide treatment.
Read More